Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
VA Office of Research and Development
The study requires a maximum of five study visits in the following order: 1. nebulized normal saline, 2. nebulized 1mg/kg of L-NAME (see below), 3. intravenous normal saline, 4. intravenous 1 mg/kg L-NAME, 5. intravenous 2 mg/kg L-Name.
Age
18–65
Sex
ALL
Healthy volunteers
Accepted
You may be eligible if
1. Written informed consent.
2. Age between 18 and 65 years.
3. Able-bodied individuals, persons with mild asthma or individuals with tetraplegia for at least one year of duration.
4. Able to perform acceptable pulmonary function tests and follow procedures.
You may not be if
1. coronary artery disease;
2. active cigarette smokers or previous smokers who stopped \<5 years ago;
3. MI or stroke within 3 months;
4. moderate to severe reduction in lung function defined as FEV1 \< 70 % predicted (except in individuals with tetraplegia);
5. hypertension;
6. medications known to affect the cardiovascular system;
7. pregnancy
8. current use of cholinesterase medication; and
Asthmatic subjects:
1. Moderate to severe disease as per spirometric indices;
2. testing within 48 hours of last administration of long acting inhaled bronchodilator;
3. testing within 7 days of last administration of glucocorticoids;
4. testing within \> 24 hours since last administration of leukotriene modifiers; and
5. testing within 8 hours of last administration of a short acting bronchodilator medication
